All patients
Age < 65y (younger) Age > 65y Age > 75y (older) BRAF mutant BRAF wild type ECOG ⩾ 1 ECOG 0 ECOG 1 Gender, female Gender, male LDH > ULN LDH ≤ULN metastasis (brain) NO metastasis (brain) YES metastasis (liver ) PD-L1 < 1% PD-L1 < 5% PD-L1 > 1% PD-L1 > 5% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) previous systemic treatment (%) previous systemic treatment NO (%) Prior anti-CTLA4 benefit NO Prior anti-CTLA4 benefit YES stage III (locally advanced) stage IIIa stage IIIb stage IIIc stage IV (metastatic) stage M0 stage M0/M1A/M1B stage M1A stage M1B stage M1C stage M1C (with brain metastasis)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
metastatic/adv melanoma (mML), immune chekpoint inhibitors vs. non active control, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results EORTC 18071, 2015 0.72 [0.58; 0.89]
0.72 [0.58 ; 0.89 ] EORTC 18071, 2015 1 0% 951 NA not evaluable deaths (OS) (extension)detailed results EORTC 18071, 2015 0.73 [0.64; 0.83]
0.73 [0.64 ; 0.83 ] EORTC 18071, 2015 1 0% 951 NA not evaluable MFSdetailed results EORTC 18071, 2015 0.76 [0.63; 0.91]
KEYNOTE 054 (all population), 2018 0.53 [0.37; 0.76]
0.66 [0.46 ; 0.93 ] EORTC 18071, 2015, KEYNOTE 054 (all population), 2018 2 67% 1,970 low not evaluable MFS (extension)detailed results EORTC 18071, 2015 0.76 [0.64; 0.90]
0.76 [0.64 ; 0.90 ] EORTC 18071, 2015 1 0% 951 NA not evaluable RFS (extension)detailed results EORTC 18071, 2015 0.75 [0.63; 0.89]
KEYNOTE 054 (all population), 2018 0.56 [0.47; 0.67]
KEYNOTE 054 (PDL1>1%), 2018 0.57 [0.43; 0.75]
0.63 [0.51 ; 0.77 ] EORTC 18071, 2015, KEYNOTE 054 (all population), 2018, KEYNOTE 054 (PDL1>1%), 2018 3 68% 2,823 low not evaluable RFS/DFSdetailed results EORTC 18071, 2015 0.75 [0.63; 0.89]
IMMUNED (N vs P ; all population), 2020 0.56 [0.33; 0.95]
IMMUNED (NI vs P ; all population), 2020 0.23 [0.12; 0.45]
KEYNOTE 054 (all population), 2018 0.57 [0.43; 0.75]
KEYNOTE 054 (PDL1>1%), 2018 0.54 [0.42; 0.69]
0.55 [0.42 ; 0.72 ] EORTC 18071, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018, KEYNOTE 054 (PDL1>1%), 2018 5 74% 3,042 low serious DMFSdetailed results KEYNOTE 054 (all population), 2018 0.60 [0.49; 0.73]
KEYNOTE 054 (PDL1>1%), 2018 0.60 [0.49; 0.73]
0.60 [0.52 ; 0.69 ] KEYNOTE 054 (all population), 2018, KEYNOTE 054 (PDL1>1%), 2018 2 0% 1,872 low not evaluable AE (any grade)detailed results EORTC 18071, 2015 7.53 [3.17; 17.90]
KEYNOTE 054 (all population), 2018 1.51 [0.96; 2.38]
3.23 [0.67 ; 15.56 ] EORTC 18071, 2015, KEYNOTE 054 (all population), 2018 2 90% 1,956 low not evaluable AE (grade 3-4)detailed results EORTC 18071, 2015 0.11 [0.08; 0.17]
KEYNOTE 054 (all population), 2018 2.03 [1.52; 2.73]
0.48 [0.03 ; 8.11 ] EORTC 18071, 2015, KEYNOTE 054 (all population), 2018 2 99% 1,956 low not evaluable AE leading to death (grade 5)detailed results IMMUNED (N vs P ; all population), 2020 0.93 [0.02; 47.58]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
0.93 [0.06 ; 15.01 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 212 low not evaluable AE leading to treatment discontinuation (any grade)detailed results IMMUNED (N vs P ; all population), 2020 3.57 [0.71; 18.07]
IMMUNED (NI vs P ; all population), 2020 39.67 [8.72; 180.45]
12.12 [1.15 ; 128.21 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 78% 212 low not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 4.90 [0.55; 43.46]
IMMUNED (NI vs P ; all population), 2020 55.77 [7.19; 432.80]
17.04 [1.57 ; 184.53 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 61% 213 low not evaluable SAE (any grade)detailed results IMMUNED (N vs P ; all population), 2020 1.27 [0.56; 2.87]
IMMUNED (NI vs P ; all population), 2020 4.55 [2.00; 10.32]
2.40 [0.69 ; 8.40 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 79% 212 low not evaluable SAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 2.51 [0.94; 6.74]
IMMUNED (NI vs P ; all population), 2020 8.75 [3.35; 22.86]
4.71 [1.39 ; 15.99 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 68% 213 low not evaluable STRAE (any grade)detailed results IMMUNED (N vs P ; all population), 2020 6.13 [1.29; 29.17]
IMMUNED (NI vs P ; all population), 2020 34.09 [7.51; 154.62]
14.61 [2.72 ; 78.57 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 58% 212 low not evaluable STRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 19.34 [1.09; 342.95]
IMMUNED (NI vs P ; all population), 2020 90.55 [5.31; 1542.75]
42.30 [5.62 ; 318.55 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable TRAE (any grade)detailed results EORTC 18071, 2015 14.40 [10.07; 20.60]
IMMUNED (N vs P ; all population), 2020 4.29 [1.74; 10.57]
IMMUNED (NI vs P ; all population), 2020 21.77 [4.78; 99.11]
KEYNOTE 054 (all population), 2018 6.05 [4.24; 8.63]
8.76 [4.52 ; 17.01 ] EORTC 18071, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018 4 80% 2,169 low not evaluable TRAE (grade 3-4)detailed results EORTC 18071, 2015 25.27 [14.14; 45.18]
IMMUNED (N vs P ; all population), 2020 5.85 [1.58; 21.65]
IMMUNED (NI vs P ; all population), 2020 39.00 [10.59; 143.61]
KEYNOTE 054 (all population), 2018 12.66 [3.87; 41.39]
17.87 [8.78 ; 36.39 ] EORTC 18071, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018 4 46% 2,169 low not evaluable TRAE leading to death (grade 5)detailed results EORTC 18071, 2015 10.16 [0.55; 186.52]
IMMUNED (N vs P ; all population), 2020 0.93 [0.02; 47.58]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
KEYNOTE 054 (all population), 2018 1.97 [0.07; 58.99]
2.63 [0.47 ; 14.86 ] EORTC 18071, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018 4 0% 2,168 low not evaluable TRAE leading to discontinuation (any grade)detailed results EORTC 18071, 2015 21.35 [13.41; 33.97]
IMMUNED (N vs P ; all population), 2020 7.29 [0.86; 61.51]
IMMUNED (NI vs P ; all population), 2020 80.95 [10.39; 630.65]
22.32 [9.86 ; 50.54 ] EORTC 18071, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 3 23% 1,157 low not evaluable TRAE leading to discontinuation (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 9.90 [0.53; 186.01]
IMMUNED (NI vs P ; all population), 2020 112.65 [6.61; 1919.31]
34.42 [3.18 ; 372.75 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 27% 213 low not evaluable Abdominal pain TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
0.92 [0.06 ; 14.87 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Acute kidney injury TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 1.87 [0.06; 56.97]
1.37 [0.10 ; 18.13 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 1.87 [0.06; 56.97]
KEYNOTE 054 (all population), 2018 1.97 [0.07; 58.99]
1.57 [0.20 ; 12.24 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018 3 0% 1,224 low not evaluable Alopecia TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
0.92 [0.06 ; 14.87 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Anaemia TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 1.87 [0.06; 56.97]
1.37 [0.10 ; 18.13 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Arthralgia TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 3.74 [0.16; 84.94]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
KEYNOTE 054 (all population), 2018 5.95 [0.30; 119.02]
3.26 [0.49 ; 21.69 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018 3 0% 1,224 low not evaluable Blood and lymphatic system disorders TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 5.72 [0.28; 116.99]
IMMUNED (NI vs P ; all population), 2020 1.87 [0.06; 56.97]
3.50 [0.36 ; 33.64 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
0.92 [0.06 ; 14.87 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Chills TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
0.92 [0.06 ; 14.87 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Colitis TRAE (grade 3-4)detailed results EORTC 18071, 2015 39.14 [5.34; 286.74]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 5.83 [0.28; 119.27]
KEYNOTE 054 (all population), 2018 10.04 [1.28; 78.73]
11.79 [3.23 ; 43.04 ] EORTC 18071, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018 4 8% 2,169 low not evaluable Cough TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
0.92 [0.06 ; 14.87 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Decreased appetite TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
0.92 [0.06 ; 14.87 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Diabetes TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
KEYNOTE 054 (all population), 2018 9.95 [0.54; 182.62]
3.28 [0.48 ; 22.60 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018 3 0% 1,224 low not evaluable Diarrhoea TRAE (grade 3-4)detailed results EORTC 18071, 2015 25.54 [6.16; 105.87]
IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs P ; all population), 2020 1.87 [0.06; 56.97]
KEYNOTE 054 (all population), 2018 1.32 [0.29; 5.92]
3.97 [0.63 ; 25.09 ] EORTC 18071, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018 4 66% 2,169 low not evaluable Dizziness TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
0.92 [0.06 ; 14.87 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Dry skin TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
0.92 [0.06 ; 14.87 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Dysgeusia TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
0.92 [0.06 ; 14.87 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Dyspepsia TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
0.92 [0.06 ; 14.87 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Dyspnoea TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
KEYNOTE 054 (all population), 2018 1.97 [0.07; 58.99]
1.25 [0.14 ; 10.76 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018 3 0% 1,224 low not evaluable Ear and labyrinth disorders TRAE (grade 3-4)detailed results IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
0.93 [0.02 ; 47.58 ] IMMUNED (NI vs P ; all population), 2020 1 0% 106 NA not evaluable Endocrine disorders TRAE (grade 3-4) detailed results EORTC 18071, 2015 42.70 [5.84; 312.15]
IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs P ; all population), 2020 10.10 [0.54; 189.78]
KEYNOTE 054 (all population), 2018 18.05 [1.04; 312.27]
16.68 [4.47 ; 62.16 ] EORTC 18071, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018 4 0% 2,169 low not evaluable Eye disorders TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 1.87 [0.06; 56.97]
1.37 [0.10 ; 18.13 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Fatigue TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
0.92 [0.06 ; 14.87 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Gastritis TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 3.81 [0.17; 86.56]
2.19 [0.19 ; 25.33 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results EORTC 18071, 2015 22.61 [8.20; 62.34]
IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs P ; all population), 2020 17.19 [0.96; 307.68]
KEYNOTE 054 (all population), 2018 5.01 [1.09; 22.98]
11.22 [4.04 ; 31.14 ] EORTC 18071, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018 4 24% 2,169 low not evaluable General disorders and administration site conditions TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 3.81 [0.17; 86.56]
2.19 [0.19 ; 25.33 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Headache TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
0.92 [0.06 ; 14.87 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Hepatitis TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 3.74 [0.16; 84.94]
IMMUNED (NI vs P ; all population), 2020 12.37 [0.67; 227.41]
KEYNOTE 054 (all population), 2018 6.99 [0.86; 56.99]
7.04 [1.58 ; 31.38 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018 3 0% 1,224 low not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results EORTC 18071, 2015 57.44 [7.90; 417.44]
IMMUNED (N vs P ; all population), 2020 3.74 [0.16; 84.94]
IMMUNED (NI vs P ; all population), 2020 28.19 [1.62; 491.24]
26.18 [5.91 ; 115.97 ] EORTC 18071, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 3 5% 1,158 low not evaluable Hypertension TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
0.92 [0.06 ; 14.87 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 5.83 [0.28; 119.27]
KEYNOTE 054 (all population), 2018 1.97 [0.07; 58.99]
2.57 [0.36 ; 18.21 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018 3 0% 1,224 low not evaluable Hypophysitis TRAE (grade 3-4)detailed results EORTC 18071, 2015 44.19 [2.67; 732.31]
IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
KEYNOTE 054 (all population), 2018 5.95 [0.30; 119.02]
6.32 [1.18 ; 33.82 ] EORTC 18071, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018 4 8% 2,169 low not evaluable Hypothyroidism TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
KEYNOTE 054 (all population), 2018 0.99 [0.02; 49.80]
0.94 [0.10 ; 9.11 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018 3 0% 1,224 low not evaluable Increase AST TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 5.72 [0.28; 116.99]
IMMUNED (NI vs P ; all population), 2020 17.19 [0.96; 307.68]
10.16 [1.26 ; 81.81 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Increased ALT TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 5.72 [0.28; 116.99]
IMMUNED (NI vs P ; all population), 2020 31.26 [1.80; 542.70]
14.02 [1.76 ; 111.54 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Increased lipase level TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.17; 4.70]
IMMUNED (NI vs P ; all population), 2020 2.72 [0.68; 10.90]
1.72 [0.60 ; 4.99 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
0.92 [0.06 ; 14.87 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Leucopenia TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
0.92 [0.06 ; 14.87 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Maculopapular rash TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 1.87 [0.06; 56.97]
1.37 [0.10 ; 18.13 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Metabolism and nutrition disorders TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs P ; all population), 2020 1.87 [0.06; 56.97]
1.85 [0.17 ; 20.75 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Musculoskeletal and connective tissue disorders TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 5.72 [0.28; 116.99]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
2.92 [0.27 ; 32.01 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Myalgia TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
1.37 [0.10 ; 18.08 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Myocarditis TRAE (grade 3-4)detailed results KEYNOTE 054 (all population), 2018 1.97 [0.07; 58.99]
1.97 [0.07 ; 58.99 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable Myositis TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
KEYNOTE 054 (all population), 2018 0.99 [0.02; 49.80]
0.94 [0.10 ; 9.11 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018 3 0% 1,224 low not evaluable Nausea TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
KEYNOTE 054 (all population), 2018 0.99 [0.02; 49.80]
0.94 [0.10 ; 9.11 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018 3 0% 1,224 low not evaluable Nephritis TRAE (grade 3-4)detailed results KEYNOTE 054 (all population), 2018 3.96 [0.18; 87.96]
3.96 [0.18 ; 87.96 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable Nervous system disorders TRAE (grade 3-4)detailed results EORTC 18071, 2015 18.45 [1.07; 319.15]
IMMUNED (N vs P ; all population), 2020 3.74 [0.16; 84.94]
IMMUNED (NI vs P ; all population), 2020 1.87 [0.06; 56.97]
5.81 [0.97 ; 34.87 ] EORTC 18071, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 3 0% 1,158 low not evaluable Neutropenia TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
0.92 [0.06 ; 14.87 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
0.92 [0.06 ; 14.87 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Pancreatitis TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
KEYNOTE 054 (all population), 2018 0.99 [0.06; 15.81]
0.95 [0.13 ; 6.79 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018 3 0% 1,224 low not evaluable Paraesthesia TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
0.92 [0.06 ; 14.87 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 1.87 [0.06; 56.97]
1.37 [0.10 ; 18.13 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Pneumonitis TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
KEYNOTE 054 (all population), 2018 7.94 [0.42; 150.67]
2.55 [0.34 ; 19.24 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018 3 0% 1,224 low not evaluable Pruritus TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
KEYNOTE 054 (all population), 2018 0.99 [0.02; 49.80]
0.94 [0.10 ; 9.11 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018 3 0% 1,224 low not evaluable Pyrexia TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 3.81 [0.17; 86.56]
2.19 [0.19 ; 25.33 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Rash TRAE (grade 3-4)detailed results EORTC 18071, 2015 10.16 [0.55; 186.52]
KEYNOTE 054 (all population), 2018 1.97 [0.07; 58.99]
5.08 [0.56 ; 46.30 ] EORTC 18071, 2015, KEYNOTE 054 (all population), 2018 2 0% 1,956 low not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
KEYNOTE 054 (all population), 2018 7.94 [0.42; 150.67]
2.55 [0.34 ; 19.24 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018 3 0% 1,224 low not evaluable Sarcoidosis TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
KEYNOTE 054 (all population), 2018 0.99 [0.02; 49.80]
0.94 [0.10 ; 9.11 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018 3 0% 1,224 low not evaluable Severe skin reaction TRAE (grade 3-4)detailed results KEYNOTE 054 (all population), 2018 5.95 [0.30; 119.02]
5.95 [0.30 ; 119.02 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results EORTC 18071, 2015 42.00 [2.53; 697.02]
IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs P ; all population), 2020 5.83 [0.28; 119.27]
KEYNOTE 054 (all population), 2018 1.97 [0.07; 58.99]
6.71 [1.40 ; 32.05 ] EORTC 18071, 2015, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018 4 0% 2,169 low not evaluable Stomatitis TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
0.92 [0.06 ; 14.87 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 1.87 [0.06; 56.97]
1.37 [0.10 ; 18.13 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Thyroiditis TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
KEYNOTE 054 (all population), 2018 0.99 [0.02; 49.80]
0.94 [0.10 ; 9.11 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018 3 0% 1,224 low not evaluable Uveitis TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
KEYNOTE 054 (all population), 2018 0.99 [0.02; 49.80]
0.94 [0.10 ; 9.11 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018 3 0% 1,224 low not evaluable Vitiligo TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
KEYNOTE 054 (all population), 2018 0.99 [0.02; 49.80]
0.94 [0.10 ; 9.11 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020, KEYNOTE 054 (all population), 2018 3 0% 1,224 low not evaluable Vomiting TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
0.92 [0.06 ; 14.87 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Weight decreased TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs P ; all population), 2020 0.93 [0.02; 47.58]
0.92 [0.06 ; 14.87 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs P ; all population), 2020 2 0% 213 low not evaluable Abdominal pain AE (grade 3-4)detailed results EORTC 18071, 2015 0.04 [0.01; 0.17]
0.04 [0.01 ; 0.17 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Colitis AE (grade 3-4)detailed results EORTC 18071, 2015 6.26 [2.61; 15.03]
6.26 [2.61 ; 15.03 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Cough AE (grade 3-4)detailed results Out of scale EORTC 18071, 2015 0.01 [0.00; 0.15]
0.01 [0.00 ; 0.15 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Decreased appetite AE (grade 3-4)detailed results EORTC 18071, 2015 0.06 [0.01; 0.46]
0.06 [0.01 ; 0.46 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Diarrhoea AE (grade 3-4)detailed results EORTC 18071, 2015 0.26 [0.18; 0.37]
0.26 [0.18 ; 0.37 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Fatigue AE (grade 3-4)detailed results EORTC 18071, 2015 0.05 [0.03; 0.10]
0.05 [0.03 ; 0.10 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Headache AE (grade 3-4)detailed results EORTC 18071, 2015 0.04 [0.01; 0.11]
0.04 [0.01 ; 0.11 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Hypophysitis AE (grade 3-4)detailed results EORTC 18071, 2015 11.01 [2.57; 47.24]
11.01 [2.57 ; 47.24 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results EORTC 18071, 2015 0.14 [0.02; 1.16]
0.14 [0.02 ; 1.16 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Increase AST AE (grade 3-4)detailed results EORTC 18071, 2015 0.80 [0.45; 1.45]
0.80 [0.45 ; 1.45 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Increased ALT AE (grade 3-4)detailed results EORTC 18071, 2015 0.97 [0.55; 1.70]
0.97 [0.55 ; 1.70 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Nausea AE (grade 3-4)detailed results EORTC 18071, 2015 0.01 [0.00; 0.07]
0.01 [0.00 ; 0.07 ] EORTC 18071, 2015 1 0% 945 NA not evaluable 0.0 100.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 03:15 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 283,284,70,235,285,68,127,128,286,69,129
- treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563,746,745,856,634,861,416,864,769,980,369,743